General Info

BioNumerik Pharmaceuticals is focused on the discovery, development and commercialization of novel drugs for the treatment of patients with cancer and the side effects often associated with many therapies. The company, utilizing mechanism-based drug discovery technologies, employs a variety of multi-disciplinary sciences, including chemistry, biology and quantum physics to identify, simulate and better understand the mechanisms by which drugs and their targets function. BioNumerik has two late-stage drugs in development. Lead candidate Tavocept, which has FDA fast-track status, may prevent nerve and kidney damage caused by cancer therapies. The firm is developing the drug with the cancer unit of Baxter and through a joint venture with an affiliate of Takeda Pharmaceutical Company. The company s BNP1350 candidate is an advanced formulation of an existing cancer drug that may defeat drug-resistant tumors. BioNumerik Pharmaceuticals maintains its corporate headquarters and research and development facilities in San Antonio.